Prolia and denosumab biosimilars — J0897, Q5136, Q5157, Q5158, Q5167

Denosumab products — the osteoporosis line

Prolia and four FDA-licensed biosimilars all bill the osteoporosis dose of denosumab: 1 mg per billing unit, 60 mg per dose. Each has its own HCPCS code, so the unit count is identical across products but the code is not. Pricing comparison lives in Current Prolia pricing.

Q5167 Enoby has no CMS Average Sales Price payment limit published in any quarter to date. Never put a Medicare dollar rate against it — verify the payer's own contracted rate instead.

Prolia vs. Xgeva — same molecule, same J-code, different product

Prolia and Xgeva are both denosumab and both bill under J0897, but they are not the same product. Prolia is a 60 mg prefilled syringe given once every 6 months for osteoporosis.

Xgeva is a 120 mg vial given monthly for skeletal-related events in cancer, giant cell tumor of bone, and hypercalcemia of malignancy — none of which are indications this page covers. Because both products share one J-code, the billed units are what separates them on the claim: 60 units for Prolia, 120 for Xgeva. Billing 60 units when the patient actually received Xgeva (or 120 when they received Prolia) is a real and common error, and the patient-assistance programs under J0897 must specify which product they cover for the same reason.

Jubbonti (Q5136)

Sandoz · denosumab-bbdz · also marketed as Wyost at the 120 mg Xgeva-equivalent dose, billed separately. Same 1 mg per unit basis as Prolia.

Stoboclo (Q5157)

Celltrion · denosumab-bmwo · also marketed as Osenvelt at the 120 mg Xgeva-equivalent dose, billed separately.

Conexxence (Q5158)

Fresenius Kabi · denosumab-bnht · also marketed as Bomyntra at the 120 mg Xgeva-equivalent dose, billed separately.

Enoby (Q5167)

Hikma · denosumab-qbde · also marketed as Xtrenbo at the 120 mg Xgeva-equivalent dose, billed separately. No CMS ASP payment limit published — confirm the payer's contracted rate before billing.

Prolia dosing, workup and co-therapy

One fixed dose, one fixed schedule, for every labeled indication — the variation that matters to a biller isn't the dose, it's what has to be documented before it and around it.

Co-therapy

Every patient on Prolia should also be taking calcium (1,000 mg) and at least 400 IU of vitamin D daily, unless they are hypercalcemic. This isn't optional supporting care — it's part of managing the hypocalcemia risk the FDA label warns about. Document it in the chart at every visit: an under-documented supplement regimen is what a payer or auditor cites when a hypocalcemia event follows a J0897 claim.

Pre-treatment workup checklist

• Correct pre-existing hypocalcemia before the first dose — it's a contraindication (E83.51), not something to treat through.
• Assess renal function. Severe renal impairment and dialysis patients carry a materially higher hypocalcemia risk, and CMS's most severe warning for this drug is specific to advanced kidney disease.
• Dental examination for patients with risk factors for osteonecrosis of the jaw, before starting therapy.

Discontinuation and missed doses

Stopping Prolia is the clinical risk, not continuing it. Bone turnover rebounds after a missed or late dose, and multiple vertebral fractures have followed discontinuation in the trial and post-marketing record — which is why patients coming off Prolia are normally transitioned to a bisphosphonate rather than stopped outright. For billing and care-coordination purposes, a missed or significantly late 6-month dose is a clinical event that should trigger outreach, and not a lapsed prior authorization.

That transition often moves the patient to a different benefit than the one that carried the J0897 claim: an oral bisphosphonate (alendronate, risedronate) runs through the pharmacy benefit, while IV zoledronic acid bills medical under its own code, J3489. Flag the hand-off in the chart so a missed transition reads as a care gap, not a closed case.

The same hand-off risk runs the other direction, toward the anabolic agents some patients are on before or after denosumab. Teriparatide (Forteo and its biosimilars) is patient-administered by daily subcutaneous injection and bills the pharmacy benefit — it carries no HCPCS J-code, so the claim never touches a J0897 workflow. Romosozumab (Evenity, J3111) is different: it is given as a monthly office injection and bills the medical benefit, the same way Prolia does.

A patient moving between teriparatide and Prolia, or between Evenity and Prolia, is moving between two different benefits and two different prior-authorization queues. A practice that treats that switch as one continuous course of therapy loses the hand-off.

Need the billing units for a patient? Convert dose to J0897 billing units →

Prolia billing reference

HCPCS

J0897 — 1 mg per billing unit. A 60 mg dose is 60 units. The same 1 mg unit basis applies to all four denosumab biosimilar HCPCS codes.

NDC

Lead NDC 55513-730-01 (Prolia, Amgen labeler 55513). Pad to 11 digits with a leading zero in the appropriate segment for CMS-1500 Box 24A.

Administration

Prolia is a subcutaneous injection, not an infusion. Administration bills 96372 alone — there is no second code for additional time, because there is no infusion to extend.

Modifiers

JZ — required when no drug is discarded; the norm on essentially every Prolia claim. JW — required for documented waste; very rare here.

Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. Because Prolia's one fixed dose (60 mg) exactly matches the one fixed syringe size (60 mg), there is normally nothing left over to waste — append JZ to the J0897 line on essentially every claim. JW only applies on the rare occasion a syringe is opened and the full dose isn't administered; document the discarded amount in the chart and bill it on a separate line, same date of service, same HCPCS code.

Modifier 25 — same-day E/M. Append modifier 25 to the same-day E/M code only if a significant, separately identifiable evaluation occurred beyond the routine pre-injection check-in, which is bundled into the administration code.

TB — 340B drug pricing. Hospitals that acquire denosumab through 340B and bill Medicare report the TB modifier, the sole 340B identifier since CMS discontinued JG on January 1, 2025.

Claim form

CMS-1500 / 837P (physician office; POS 11) field map for a J0897 claim.

Calculate units & JW/JZ →

Prolia coverage

• 22 of 27 commercial payer policy sets require prior authorization
• 14 name a preferred denosumab product
• 27 of 30 commercial payer policy sets hold a denosumab policy at all — three (bcbs_tn, hmsa, kaiser) do not
• 9 of 27 carry a site-of-care rule
• 585 individual coverage rules exist across those 27 payers, covering covered indications, clinical prerequisites, preferred products, dosing, quantity limits, contraindication exclusions, site of care, and step therapy
• Because Prolia and Xgeva share J0897, a payer's denosumab policy may set different rules by indication rather than by product — verify the diagnosis on file matches an osteoporosis indication, not a cancer one

ICD-10 codes by indication

Use the most specific code supported by chart documentation. Each indication has a distinct code, and several require a second code for the underlying cause.

E83.51 hypocalcaemia is a contraindication, not an indication — correct it before the first dose, and do not submit it as the reason for treatment.

See Medicare covered diagnoses for denosumab for the MAC-level ICD-10 ranges.

Check the patient's actual policy: See Prolia coverage by payer →

Current Prolia pricing

Medicare ASP+6%: $30.101 / 1 mg · $1,806.06 / 60 mg. Add the $15.36 administration allowance for 96372 and the claim totals $1,821.42 before the sequester.

Sequestration reduces Medicare's 80% share by 2%. Commercial plans pay a contracted rate that differs by payer and state.

2 doses a year (60 mg SC every 6 months) at $1,821.42 per dose — drug plus 96372 administration — total $3,642.84 before the sequester. That is the full annual drug-plus-administration cost for a patient staying on schedule, before benefits or assistance.

Look up commercial reimbursement →

Patient cost

The patient's actual responsibility depends on: payer allowed rate · remaining Part B deductible ($283 in 2026) · benefits · − assistance · = patient responsibility. At 20% coinsurance with the deductible already met, a Medicare patient's share of one dose is roughly $364.28.

Calculate a Prolia patient estimate →

Copay & financial assistance

Manufacturer and foundation programs exist for Prolia, but because Prolia and Xgeva share J0897, always confirm a program covers the 60 mg osteoporosis product specifically before pointing a patient to it — a program scoped to Xgeva does not apply here. Check current open/closed status before assuming availability; status changes without notice.

See current Prolia assistance programs →

Common Prolia denials & fixes